Eur Respir J 2002; 20:59-65
Copyright ©ERS Journals Ltd 2002
Pulmonary arterial hypertension and type-I glycogen-storage disease: the serotonin hypothesis
M. Humbert1,
P. Labrune2,
O. Sitbon1,
C. Le Gall1,
J. Callebert3,
P. Hervé1,
D. Samuel4,
R. Machado5,
R. Trembath5,
L. Drouet6,
J-M. Launay3 and
G. Simonneau1
1 Unité Propre de Recherche de l'Enseignement Supérieur (UPRES) 2705, Service de Pneumologie, Centre des Maladies Vasculaires Pulmonaires and 2 UPRES 2704, Service de Pédiatrie, Hôpital Antoine Béclère, Université Paris Sud, Clamart, 4 Centre Hépato-Biliaire, Hôpital Paul Brousse, Villejuif and 6 Service d'Immuno-hématologie and 3 Service de Biochimie, Hôpital Lariboisière, Assistance Publique, Hôpitaux de Paris, Paris, France. 5 Division of Medical Genetics, Depts of Medicine and Genetics, University of Leicester, Leicester, UK
CORRESPONDENCE: M. Humbert, Service de Pneumologie, Centre des Maladies Vasculaires Pulmonaires, Hôpital Antoine Béclère, 157 rue de la Porte de Trivaux, 92140, Clamart, France. Fax: 33 146303824. E-mail: humbert@ipsc.u-psud.fr
Keywords: pulmonary hypertension, serotonin, type-I glycogen-storage disease
Received: July 6, 2001
Accepted January 7, 2002
This study was supported by grants from Universite Paris-Sud, Institut National de la Santé et de la Médicale (INSERM) and Association Francaise contre les Myopathies (AFM).
A case of pulmonary arterial hypertension in a patient with type-Ia glycogen-storage disease, a rare autosomal recessive disorder caused by a deficiency of glucose-6-phosphatase is reported in this study. It has been suggested that the occurrence of pulmonary arterial hypertension in type-Ia glycogen-storage disease could be due to an abnormal production of vasoconstrictive amines such as serotonin.
To test this hypothesis, plasma serotonin concentrations were prospectively measured in 13 patients with type-Ia glycogen-storage disease, one patient with severe pulmonary hypertension and type-Ia glycogen-storage disease, 16 patients displaying severe pulmonary arterial hypertension, and 26 normal healthy controls.
Elevated plasma serotonin concentrations were found in patients with either severe pulmonary arterial hypertension (38.8±7.3 nmol·L1) or type-Ia glycogen-storage disease (36.8±11.5 nmol·L1), as compared with controls (8.8±0.6 nmol·L1, p<0.001). Plasma serotonin was dramatically elevated in the patient with type-Ia glycogen-storage disease and pulmonary arterial hypertension (113.4 nmol·L1).
It is concluded that type-Ia glycogen-storage disease may be another condition in which abnormal handling of serotonin is one event in a multistep process leading to severe pulmonary arterial hypertension.
This article has been cited by other articles:

|
 |

|
 |
 
G. Simonneau, I. M. Robbins, M. Beghetti, R. N. Channick, M. Delcroix, C. P. Denton, C. G. Elliott, S. P. Gaine, M. T. Gladwin, Z.-C. Jing, et al.
Updated Clinical Classification of Pulmonary Hypertension
J. Am. Coll. Cardiol.,
June 30, 2009;
54(1_Suppl_S):
S43 - S54.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. V. McLaughlin, S. L. Archer, D. B. Badesch, R. J. Barst, H. W. Farber, J. R. Lindner, M. A. Mathier, M. D. McGoon, M. H. Park, R. S. Rosenson, et al.
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association Developed in Collaboration With the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association
J. Am. Coll. Cardiol.,
April 28, 2009;
53(17):
1573 - 1619.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Writing Committee Members, V. V. McLaughlin, S. L. Archer, D. B. Badesch, R. J. Barst, H. W. Farber, J. R. Lindner, M. A. Mathier, M. D. McGoon, M. H. Park, et al.
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: Developed in Collaboration With the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association
Circulation,
April 28, 2009;
119(16):
2250 - 2294.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Task Force members, N. Galie, A. Torbicki, R. Barst, P. Dartevelle, S. Haworth, T. Higenbottam, H. Olschewski, A. Peacock, G. Pietra, et al.
Guidelines on diagnosis and treatment of pulmonary arterial hypertension: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology
Eur. Heart J.,
December 2, 2004;
25(24):
2243 - 2278.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Simonneau, N. Galie, L. J. Rubin, D. Langleben, W. Seeger, G. Domenighetti, S. Gibbs, D. Lebrec, R. Speich, M. Beghetti, et al.
Clinical classification of pulmonary hypertension
J. Am. Coll. Cardiol.,
June 16, 2004;
43(12_Suppl_S):
5S - 12S.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Humbert and R.C. Trembath
Genetics of pulmonary hypertension: from bench to bedside
Eur. Respir. J.,
September 1, 2002;
20(3):
741 - 749.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the European Respiratory Society.
|